MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q1
hinzugefügt 15.05.2023
Sorrento Therapeutics Anteile 2011-2026 | SRNE
Anteile Jährlich Sorrento Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 295 M | 230 M | 133 M | 106 M | 69.7 M | 50.4 M | 36.9 M | 26.7 M | 15 M | 11.4 M | 9.92 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 295 M | 9.92 M | 89.4 M |
Anteile Vierteljährlich Sorrento Therapeutics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 543 M | 523 M | 452 M | 403 M | 337 M | 315 M | 299 M | 290 M | 281 M | 268 M | 251 M | 217 M | 183 M | 155 M | 131 M | 123 M | 122 M | 122 M | 117 M | 101 M | 84.9 M | 80.5 M | 76.9 M | 70.3 M | 50.9 M | 58.6 M | 66.2 M | 46.5 M | 38 M | 37.8 M | 37.3 K | 36.3 M | 36.2 M | 29.6 M | 28.5 M | 25.3 K | 23.1 K | 23 M | 14.1 M | 13.4 M | 12.3 M | 12 M | 12 M | 11.2 M | 261 M | 262 M | 262 M | 262 M | 262 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 543 M | 23.1 K | 151 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
16.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
1.56 B | $ 18.06 | - | $ 28.2 B |  Japan |
 |
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 19.44 | -0.46 % | $ 909 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
6.18 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
187 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
25.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
60.8 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Protara Therapeutics
TARA
|
42.8 M | $ 5.03 | -3.08 % | $ 215 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
Tarsus Pharmaceuticals
TARS
|
41.8 M | $ 67.0 | -0.3 % | $ 2.8 B | USA |
 |
bluebird bio
BLUE
|
110 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
12.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Theravance Biopharma
TBPH
|
50.3 M | $ 14.9 | -1.91 % | $ 750 M |  Cayman-islands |
 |
Avid Bioservices
CDMO
|
63.2 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
15.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
255 M | $ 1.2 | -6.97 % | $ 306 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B | Cayman-islands |
 |
Bio-Techne Corporation
TECH
|
158 M | $ 51.31 | -2.65 % | $ 8.08 B | USA |
 |
Tenax Therapeutics
TENX
|
39.2 M | $ 14.64 | -2.2 % | $ 574 M | USA |
 |
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
69.9 K | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
20.5 M | $ 1.07 | -2.29 % | $ 21.9 M | Israel |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
1.14 B | $ 28.76 | -3.43 % | $ 32.9 B | Israel |
 |
Enochian Biosciences
ENOB
|
165 M | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
57.3 M | $ 2.03 | -1.46 % | $ 116 M | USA |
 |
Eton Pharmaceuticals
ETON
|
26.9 M | $ 23.81 | 1.51 % | $ 641 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
9.55 M | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 46.38 | -2.45 % | $ 4.17 B |  Schweiz |